Technical Data
M1750-01D
MAGE A
Description:
The MAGE-A protein is expressed in many types of tumors including melanoma, breast and lung. However, in normal tissues, it is only present in adult testis and placenta. The family of MAGE-A proteins includes MAGE-1, -2, -3, -4, -6, -10, and -12. MAGE-1, -3, -6 and -10 are able to recognize specific cytolytic T lymphocytes derived from tumors or peripheral blood. Additionally, MAGE-3 shows HLA class II restricted epitopes. Therefore, MAGE-A is regarded as a possible
immunotherapy candidate, with clinical studies currently underway involving immunization with MAGE-1 and -3 peptides.

Applications:
Suitable for use in ELISA, Immunocytochemistry, Immunohistochemistry, Immunofluorescence, Immunoprecipitation and Western Blot. Other applications have not been tested.

Recommended Dilution:
ELISA (Native): 0.1-1ug/ml
Immunocytochemistry: 10ug/ml
Immunohistochemistry (Frozen sections): 10ug/ml
Immunofluorescence: 10ug/ml
Immunoprecipitation (Native): 10ug/ml
Western Blot: 1-3ug/ml
Optimal dilutions to be determined by the researcher.

Positive Controls:
Human SK-MEL-37 melanoma cell lysates.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. 
TypeIsotypeCloneGrade
MabIgG2a6A111Affinity Purified
SizeStorageShippingSourceHost
100ug-20°CBlue IceHumanMouse
Concentration:
~0.5mg/ml
Immunogen:
Full-length recombinant human MAGE-A
Purity:
Purified by Protein A chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 0.1% sodium azide.
Specificity:
Recognizes different members of the human MAGE-A family: MAGE-1, -2, -3, -4, -6, -10 and -12. MAGE-10 has a molecular weight of ~72kD. The rest of the MAGE-A proteins have molecular weights ~45-50kD.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. De Plaen, E., et al., Immunogenetics 40: 360-369 (1994). 2. Zorn, E., et al., Eur. J. Immunol. 29: 602-607 (1999). 3. Rimoldi, et al., Int. J. Cancer 86: 749-751 (2000).